34 results about "Vascular Calcifications" patented technology

The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.

The invention relates to the use of a poly(ADP ribose) polymerase (PARP) inhibitor and / or a tetracycline, for treating, preventing or ameliorating medial vascular calcification or intimal atherosclerotic calcification, and to pharmaceutical compositions comprising PARP inhibitors or tetracycline.

The inventors demonstrate that the phosphatase and hydrolase domains of soluble epoxide hydrolase (sEH) regulate the cardiovascular calcification process and revealed that inhibition of the phosphatase domain of sEH could represent a new pharmacological target in the prevention of cardiovascular calcification. The present invention thus relates to a therapeutically effective amount of an inhibitor of phosphatase activity of soluble epoxide hydrolase for use in a method of treating cardiovascular calcification in a subject in need thereof.

The invention discloses a long-acting sustained-release cardiovascular coating material with dual functions of anti-calcification and anti-proliferation and a preparation method thereof; the preparation method is as follows: firstly polishing, cleaning and drying the base material to be modified and modified ; Then place the treated substrate in dopamine solution, react at 10-30°C for 0.5-2h; then put the reacted substrate into biomacromolecule solution, heparin solution and biomacromolecule solution in sequence , respectively soaked for 10 minutes, and then transferred to drug-loaded micelles for soaking for 20 minutes; finally, the soaking step was repeated 1 to 30 times to obtain the final product. Using this method, a cardiovascular coating material with excellent mechanical properties and sustained drug release can be prepared. By loading the drug-loaded micelles with anti-vascular calcification drugs and anti-vascular smooth muscle hyperplasia drugs, it can effectively support the cardiovascular system. Anti-calcification and anti-proliferation properties of vascular stent coating materials.

The invention discloses a medicine for protecting internal arteriovenous fistula and a preparation method thereof. The medicine is mainly prepared from cassia bark, earthworm, frankincense, myrrh and safflower. The medicine has the effects of warming channel and promoting circulation of Qi, promoting blood circulation to remove blood stasis, and relieving swelling and pain, has a protective effect on vascular endothelial and smooth muscles, can promote internal fistula maturation and effectively protect internal fistula blood vessel, can reduce vascular stenosis, thrombosis and vascular calcification complications, and has the advantages of quick effect, small local drug delivery side effect, high safety, convenience in use, and the like.

The present invention belongs to the technical field of medicine, and relates to the new application of κ-opioid receptor agonist U50,488H, and more specifically, relates to the application of κ-opioid receptor agonist U50,488H in the preparation of drugs for treating vascular calcification. Experiments have proved that its mechanism of inhibiting vascular calcification is: by reducing the expression of PFKFB3, and then inhibiting the level of glycolysis, thereby inhibiting the calcification of VSMCs induced by high phosphorus. The research results provide a potential drug target for the clinical treatment of vascular calcification and treatment strategies.

The invention discloses a plasma marker, a primer pair and a kit for a diagnosis of vascular calcification and an application. The invention discloses a plasma miRNA marker miR-32-5p used for the diagnosis of the vascular calcification. The marker and primers thereof can be used for preparing a diagnostic kit which is used for the clinical diagnosis, prevention and detection of the vascular calcification.

The invention belongs to the technical field of vascular calcification treatment, and more specifically relates to the application of iron sucrose in the preparation of medicaments for treating vascular calcification induced by hyperphosphatemia. Hyperphosphatemia causes oxidative stress damage in vascular smooth muscle cells, and then induces vascular smooth muscle cells to transform into osteoblast phenotype, and finally develops into vascular calcification. However, it is found in the experiment of the present invention that iron sucrose can interfere with the formation of inorganic phosphorus in the blood. Transmembrane transport, inhibit the expression of phosphorus transmembrane transporter, antagonize the oxidative stress damage induced by hyperphosphatemia, and thus have the effect of treating, alleviating or inhibiting vascular calcification induced by hyperphosphatemia.